Close Menu

This article has been updated to note the correct phase of the study being conducted. 

NEW YORK – Phoenix-based Ivy Brain Tumor Center, part of the Barrow Neurological Institute, Tuesday announced that the first patient has received QED Therapeutics' infigratinib in a Phase 0 clinical trial investigating the drug in high-grade gliomas driven by FGFR genetic alterations.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Jun
16
Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.